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guidelines recommendations and positive effect of ACE inhibitors on hypertension
control, the use of ACE inhibitors in hypertensive patients suffering from diabetes
mellitus was suboptimal at Penang Hospital.
PCV20
DURATION OF ACTION OF ALISKIREN IN HYPERTENSIVE PATIENTS WITH
DIABETES – IMPLICATIONS FOR CONTROL OF BLOOD PRESSURE IN REAL-
WORLD USE IN IMPERFECTLY ADHERENT PATIENTS
Lowy A, Brede Y
Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: Diabetes increases cardiovascular (CV)/renal risk and thus also in-
creases the importance of optimal control of blood pressure (BP), which is generally
poor among hypertensive patients with diabetes. Poor adherence to antihyperten-
sives is common. Electronic monitoring has shown that treatment lapses among
hypertensives frequently exceed the duration of action of most antihypertensives,
allowing the BP to rise, and reducing these drugs’ real-world effectiveness by in-
creasing CV risk. Use of long-acting antihypertensives may improve BP control
among subjects who, like most, miss doses occasionally. Aliskiren, a direct renin
inhibitor, has been shown in the general hypertensive population to suppress BP
well beyond its 24-hour dosing interval. Its BP-lowering effect is almost uninflu-
enced by a single missed dose, and remains strong after treatment interruptions of
a week (longer than almost all dosing errors). This study examines the duration of
action of aliskiren among hypertensive patients with diabetes. METHODS: BP data
from one to 28 days post-withdrawal, from diabetic subjects in six clinical trials,
were modeled to estimate the extent to which use of aliskiren will ameliorate the
effects of imperfect adherence among diabetic subjects, compared to other
antihypertensives. RESULTS: Thirty-four diabetic subjects had their BP measured
24 hours after treatment withdrawal (48 hours after the last dose). The mean (95%
CI) increase in systolic BP from pre-withdrawal baseline was 0.8 (-3.1 to 4.7)
mmHg. Seventy-three diabetic subjects had their BP measured either six or seven
days after withdrawal. The mean (95% CI) increase in systolic BP from the pre-
withdrawal baseline was 3.4 (0.8 to 6.1) mmHg. CONCLUSIONS:Among diabetics,
as in the general hypertensive population, aliskiren retains much of its effect for a
week after stopping treatment. Its duration of action in diabetic subjects covers the
majority of dosing errors. This may confer advantages over other treatments.
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CLINICAL EFFICACY OF BISOPROLOL COMPARED TO ATENOLOL IN REDUCING
THE IN-CLINIC AND AMBULATORY BLOOD PRESSURE IN HYPERTENSIVE
PATIENTS
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OBJECTIVES: The objective was to evaluate the clinical efficacy of bisoprolol com-
pared to atenolol in reducing the in-clinic and ambulatory blood pressure in pa-
tients with mild to moderate hypertension.METHODS: Studies were retrieved from
Embase, Pubmed, and Cochrane databases using relevant search strategies. Ran-
domised controlled trials which compared bisoprolol with atenolol were included
according to pre-specified inclusion/exclusion criteria. The outcomes of interest
were reduction in in-clinic systolic/diastolic blood pressure, 24-hour ambulatory
BP (ABP), and reduction in heart rate. Two reviewers independently extracted data
from the included studies. Data was meta-analysed using RevMan (v5). RESULTS:
Of the 1056 studies identified, 11 studies met the inclusion criteria. In total, 624
patients were randomised to bisoprolol, and 683 were randomised to atenolol.
Seven of the included studies were double-blind, three were single-blind and one
was open-label study. The Jadad score of eight studies was 3 and were of high
quality. The study duration of included studies ranged from 8-weeks to 52-weeks.
Results of meta-analysis showed a significantly better reduction of clinical systolic
BP with bisoprolol compared to atenolol (WMD: 3.07 (1.79, 4.35, p0.00001). The
reduction in clinical diastolic BP was significantly better with bisoprolol compared
to atenolol (2.68 (1.88, 3.48, p0.00001). The systolic ABP was significantly reduced
with bisoprolol compared to atenolol (p0.001). The reduction in diastolic ABP was
more with bisoprolol but was not significantly better. A significantly better reduc-
tion in heart rate was achieved with bisoprolol compared to atenolol (1.81 (0.97,
2.65, p0.0001).CONCLUSIONS:This review has included the evidence to date with
regards to reduction of clinical and ambulatory blood pressure with bisoprolol
compared to atenolol. This review concludes that bisoprolol is significantly better
than atenolol in effectively reducing the in-clinic BP, ambulatory BP and heart rate
in patients with mild to moderate essential hypertension.
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OBJECTIVES: To examine the geographic variation trends in the annual prevalence
of critical limb ischemia (CLI) in the US elderly population. METHODS: Using na-
tional medical claims data from 2006 through 2008, all patients who were aged 65
years or older and diagnosed with CLI were identified. The direct standardization
method was used to assess year, age, gender, race and diabetes-adjusted preva-
lence of CLI. The change in prevalence of CLI over the 3 years was assessed and the
variation in the prevalence of CLI was tested by state. RESULTS: Geographic vari-
ation in the prevalence of CLI was obtained for patients over the age of 65 when
adjusted by age, gender, race and diabetes status. Although approximately con-
stant prevalence of CLI was reported in Utah (less than 0.15%) and Maryland
(greater than 0.30%), a progressively increasing prevalence of CLI was observed in
Montana (2006: 0.149%; 2007: 0.163.%; 2008: 0.277%) and Delaware (2006: 0.245%;
2007:0.247%; 2008: 0.330%) while progressively decreasing prevalence of CLI was
observed in Arkansas, Colorado, Georgia, Ohio, Virginia, West Virginia, and Wash-
ington. The total trend over 3 years followed the pattern of higher rates in eastern
states and lower rates in western states. CONCLUSIONS: The spatial distribution of
CLI prevalence is uneven and strongly suggests a geographic variation of CLI risk
areas. Targeted prevention and treatment could help gain better control of CLI in
the United States.
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OBJECTIVES: To use a novel linkage database to describe prescribing patterns in
patients discharged from hospital with acute coronary syndrome (ACS) over a pe-
riod of changing national guidelines. METHODS: Unique identifiers were used to
link patients in a hospital registry (Myocardial Ischaemia National Audit Project),
with longitudinal primary care data (General Practice Research Database). This
retrospective observational study examined post-discharge prescribing patterns
for unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) and ST
elevation MI (STEMI). The population comprised patients 40 years, hospitalised
for ACS from 2003-2009, discharged home, with 3 months follow-up. Patients
were followed from discharge until death, or censoring. A patient was classified as
discontinued if they had no further prescription within the duration of a prescrip-
tion plus a grace period of 90 days. RESULTS: Of the 7,888 linked patients with at
least 3 months of follow-up, 865 had a discharge diagnosis of UA, 4108 NSTEMI and
2915 STEMI. Overall 412(48%) UA, 2820(69%) NSTEMI and 1830(63%) STEMI patients
were treated with clopidogrel in primary care within 3 months of discharge. The
proportion of UA patients treated remained relatively stable over the study period
(2003:47%, 2009:38%), in contrast prescribing increased in NSTEMI (2003:41%, 2009:
78%) and STEMI patients (2003:24%, 2009:87%). Statin use was high in all three
groups (734(85%) UA, 3609(88%) NSTEMI, 2784(96%) STEMI) and remained so
throughout the study period. The median time until discontinuation of medicine
was 12 months for clopidogrel and24 months for statin across all three ACS types.
Patterns of discontinuation remained constant across all study years.
CONCLUSIONS: The proportion of patients with STEMI and NSTEMI treated with
clopidogrel increased from 2003 to 2009, in line with national guideline recommen-
dations. However there was no evidence that clinicians differentiated length of
therapy by type of ACS.
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OBJECTIVES: The aim of the study was to analyze use of ACE inhibitors in Serbia
compared with Montenegro in year 2009. METHODS: Data about use of ACE inhib-
itors in Serbia and in Montenegro in 2009 taken from Republic Institute for Health
Insurance from Serbia and from Health Service Fund of Montenegero. RESULTS:
Use of ACE inhibitors in Serbia in 2009 was 179,26 DDD/1000 inh/day and in Mon-
tenegro was 83,32 DDD/1000 inh/day. In Serbia 5.977.289,00€has been spent for ACE
inhibitors and in Montenegro 2.488.464,95€ in the same year. In Serbia on the first
place is enalapril with 78,32 DDD/1000 inh/day or 44,43%, on the second place
fosinopril with 20,09 DDD/1000 inh/day or 11,40%, while on the third place is
ramipril with 19,11 DDD/1000 inh/day or 10,84% of total drug utilization in this
subgroup. Amount spent on enalapril was 1.717.416,00€ or 28,73%, on fosinopril
1.116.972,00€ or 18,69%, and on ramipril 470.937,00€ or 7,88% of total finances spent
on this subgroup C09 in year 2009. In Montenegro on the first place are lisinopril
and hydrochlorothiazide with 19,62 DDD/1000 inh/day or 23,55%, on the second
place are fosinopril and hydrochlorothiazide with 12,77 DDD/1000 inh/day or
15,33%, while on the third place is fosinopril with 11,92 DDD/1000 inh/day or 14,31%
of total drug utilization inside this subgroup. Money spent on lisinopril and hydro-
chlorothiazide are 425.547,30€ or 17,10%, on fosinopril and hydrochlorothiazide
762.333,74€ or 30,63%, and on fosinopril 533.307,43€ or 21,43% of total finances
spent on this subgroup C09 in the year 2009. CONCLUSIONS: Comparing the con-
sumption of ACE inhibitors in Serbia and Montenegro in the year 2009, it becomes
clear that the combination of ACE inhibitors with diuretics is most frequently used
in Montenegro, while in Serbia the use of this combination is on the the fifth place
in this group of drugs.
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OBJECTIVES: To characterise patients with atrial fibrillation (AF) in a UK secondary
care centre. METHODS: Eligible patients admitted to Llandough Hospital (Cardiff,
UK) as an emergency with AF (ICD10 code: I48X), and discharged between 1/10/2009
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and 31/03/2010, were identified through examination of electronic patient records.
Exclusion criteria included patients with atrial flutter (AFl), or an ICD10 code indi-
cating prior inpatient attendance for AF since 1995. Patient notes were reviewed
manually and an anonymised data collection template completed by the clinician
for analysis. RESULTS: Of the 126 patients meeting the inclusion criteria, the notes
of 7 patients were unobtainable and 8 with a diagnosis of AFl were excluded. The
majority of patients were symptomatic at presentation (56%) and less than half
were male (41%). Within the study population, the frequency of patients with AF
increased with age, peaking at 80-89 years (45% of the study sample). Method of
admission was primarily through A&E or GP referral (48% each); with 50% of A&E
admissions being for symptomatic AF, compared with 60% of those referred via a
GP. Almost half the study population were recorded with “first detected AF” (47%);
67% of whom were symptomatic, compared to 47% being symptomatic in patients
recorded as “not first detected AF”. The majority of patients were reported to have
1 or 2 of the pre-defined co-morbidities of interest (29% each); one fifth had no
co-morbidities. The most common co-morbidities were hypertension (51%), isch-
aemic heart disease (20%), heart failure (18%), diabetes (16%) and pulmonary dis-
ease (15%). CONCLUSIONS: Results from this study demonstrate the majority of
patients presenting to secondary care with AF have multiple associated co-mor-
bidities, which are known to influence the management and treatment strategy,
and long-term complications. Further up-to-date epidemiological studies, which
describe the history, management and prognosis of patients with AF, are required.
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REAL WORLD ADD-ON AND SWITCH PATTERNS FOR PLATELET AGGREGATION
INHIBITORS
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OBJECTIVES: To analyze the add-on and switch patterns for patients who dis-
pensed platelet aggregation inhibitors, excluding heparin (acetylsalicylic acid,
clopidogrel, and dipyridamole) in the South-West region of Sweden. METHODS:
This was a retrospective database study of medication utilization amongst patients
from the South-West region of Sweden (1.5 million inhabitants). All patients who
dispensed platelet aggregation inhibitors (B01AC), excluding heparin, from 2006 to
2009 were included in the study. A dispatch was classified as new, switch, add-on,
or continuation. All dispatches were annotated, at the ATC level, as either new (no
other anticoagulant within 105 days), add-on (another anticoagulant dispatched
both before and after), switch (another anticoagulant dispatched before, but not
after), or continuation (dispatched same ATC-code within 105 days). RESULTS: 163
330 patients had at least one B01AC filled prescription. The total number of dis-
patches for these patients were 3 327 499. 96% of all patients had been dispatched
acetylsalicylic acid (ASA), 11% clopidogrel and 6% dipyridamole. ASA was dis-
patched as a new prescription in 17% of all dispatches, in 0.5% as add-on, 0.5%
as switch, and in 83% as continuation. For clopidogrel the distribution was 17%
(new), 4% (add-on), 3% (switch), and 77% (continuation). For dipyridamole the dis-
tribution was 7%, 18%, 8%, and 68%. CONCLUSIONS: Not surprisingly ASA was by
far the most common treatment. ASA and Clopidogrel both had first line treatment
profiles, of which it was most pronounced for ASA (1% add-on or switch). Dipyr-
idamole is used more as an add-on or switch therapy with 18% as add-on, 8% as
switch, and only 7% as new dispatches.
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FREQUENCY OF ADVERSE DRUGS EVENTS (ADES) AS POSSIBLE CAUSES OF
REQUEST OF DRUGS NOT INCLUDED IN ESSENTIAL MEDICINES LIST IN
COLOMBIA
Buendia Rodriguez JA
Universidad de Buenos Aires, Buenos Aires, Argentina
OBJECTIVES: To describe the frequency of adverse drugs events (ADEs) as possible
causes of request of drugs not included in essential Medicines list in Colombia
METHODS: This was a retrospective, descriptive study developed in a private med-
ical insurance company in Bogota, Colombia. Data were obtained from drug re-
quest form of drugs not included in a national essential Medicines list. We analyzed
the content of the notes to identify the records related to the occurrence of ADEs in
the period 2005 to 2008. Information concerning the adverse event and the drug
involved was recorded in a data collection instrument developed by the research-
ers. The pharmacological classification of drugs was performed according to the
Anatomical Therapeutic Chemical Classification System (ATC). Univariate descrip-
tive statistical analysis was performed RESULTS: A total of 116 cases of ADEs were
detected. The level 1 groups of the ATC of drugs with greater frequency of ADEs
were the cardiovascular agents (66; 47.15%), nervous system agents (34; 23.7 %) and
antineoplastic and immunomodulating agents (21; 14.7 %). The great majority was
cases of light severity (89; 62.7 %) and classified as possible (66; 48.4 %).
CONCLUSIONS:We conclude that our study encourages the private medical insur-
ance companies in developing countries to design pharmacosurveillance pro-
grams; recognizing the importance of looking for new sources of report of adverse
reactions to diminish the under-notification of ADEs.
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OBJECTIVES: Hypertension is a leading global risk factor for the burden of cardio-
vascular disease. Data about changes in hypertension control are important to set
intervention priorities. We conducted a systematic review and meta-analysis of
epidemiological studies to determine the control of hypertension in Spain over the
last decade. METHODS: A search of PubMed/MEDLINE, SCOPUS and IME was per-
formed for epidemiological studies conducted in Spain (since 2000) with data on
control rates for hypertension. The primary outcome was the prevalence of uncon-
trolled hypertension defined as the percentage of patients having systolic blood
pressure (SBP)  140 mmHg and/or diastolic blood pressure (DBP)  90 mmHg. For
populations at risk (e.g. patients with diabetes), the definition was SBP 130 mmHg
and/or DBP  80-85 mmHg. Pooled-prevalence estimates and 95% confidence in-
tervals (95% CI) were determined by random-effects models using the inverse vari-
ance method. Heterogeneity was assessed using Cochran’s Q and I2 statistics.
RESULTS: Seventy-six studies evaluating 341,632 patients (79% with hypertension)
met the inclusion criteria. Among hypertensive patients, the overall pooled-prev-
alence of uncontrolled hypertension ( 140/90 mmHg) was 67.0% (95% CI: 64.1% to
69.9%), but was 87.6% (95% CI: 86.2 to 89.0%) when the most restricted definition (
130/80-85 mmHg) was used for patients at risk. The test for heterogeneity was
significant (P0.001). Using metaregression analyses, we showed that the preva-
lence of uncontrolled hypertension did not change significantly over time, but the
percentage of patients receiving at least two antihypertensive drugs increased
(P0.032, and 0.001). CONCLUSIONS: In Spain, the control of hypertension is far
from optimum and does not appear to have improved in recent years despite the
increased intensity of therapy. Patients at risk with comorbidities appear to be
controlled worse.
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RECENT IN-HOSPITAL MORTALITY TRENDS AMONG PATIENTS WITH HEART
FAILURE IN THE NETHERLANDS
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OBJECTIVES: Recent in-hospital mortality data among heart failure (HF) patients in
the The Netherlands are lacking. This study described in-hospital mortality rates
among HF patients in the The Netherlands from 2005 to 2009. METHODS: The
PHARMO database network includes, among other things, hospitalization records
of approximately 3.2 million residents in the The Netherlands. From this database,
all patients with a hospitalization for HF between 2005 and 2008 were selected. The
date of the first HF admission was defined as the index date. Patients hospitalized
for HF in the 12 months prior to index date were excluded. Patients were followed
from index date until end of data collection, death, or a maximum of 12 months,
whichever occurred first. Crude mortality rates over time were determined during
index HF admission, any HF readmission, and during any all-cause readmission .
RESULTS: The study included 9786 patients with an index HF admission. Mean (
SD) age was 77 ( 11) years and 52% were female. During index HF admission (mean
(SD) length of stay (LOS):11 (10) days) 10% of patients died. Hence, 8,850 patients
were at risk for readmission. During follow-up, 1,563 (18%) patients were readmit-
ted for HF and 4,542 (51%) patients had an all-cause readmission. In-hospital mor-
tality during HF readmission (mean (SD) LOS: 11 (9) days) was also 10%. In-
hospital mortality during all-cause readmission (mean (SD) LOS: 7 (11) days),
was 5%. Mortality rates over time from 2005 to 2009 were stable. Mean (SD) num-
ber of days between hospital (re)admission and death was 10 (13) days for the
index HF admission and 12 (12) days for both HF readmission and all-cause read-
mission (12 (15) days). CONCLUSIONS: In most recent years, in-hospital mortality
remains unchanged with 10% of HF patients dying during HF admission.
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OBJECTIVES: Hospital admissions are common among heart failure (HF) patients
and contribute to the significant clinical and economic burden of HF. This study
determined rates, length of stay (LOS) and costs of HF (re)admissions. METHODS:
The PHARMO database network includes, among other things, hospitalization re-
cords of approximately 3.2 million residents in the The Netherlands. From this
database, all patients with a primary hospital discharge code for HF between 2005
and 2008 were selected. Date of first HF admission was defined as index date.
Patients hospitalized for HF in the 12 months prior to index date were excluded.
Patients were followed from index date to end of data collection, death, or a max-
imum of 12 months, whichever occurred first, in order to assess primary hospital-
izations for HF within one year, i.e. HF readmissions . Main outcomes for each
identified HF (re)admission were LOS (in days) and costs per (re)admission (amount
paid in €). RESULTS:The study included 9,786 patients with an index HF admission.
Mean ( SD) age was 77 ( 11) years and 52% were female. Mean ( SD) LOS was 11
 10 days and mean ( SD) hospitalization costs of index HF admission were €8,650
( €9,100). During the index HF admission 936 patients died, therefore 8,850 pa-
tients were at risk for a HF readmission. Of those patients, 1,563 patients were
readmitted for HF within one year. Overall, one-year HF readmission rate was 21.8
per 100 person years. Mean ( SD) LOS of first HF readmission was 10 10 days and
mean ( SD) hospitalization costs of first HF readmission were €8,850 ( €8,450).
CONCLUSIONS: One fifth of patients hospitalized for HF in the The Netherlands
have a subsequent HF admission within one year. Overall, costs of index HF admis-
sion and first HF readmission are similar.
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